Search
Momelotinib
go.drugbank.com/drugs/DB11763ApprovedInvestigationalMomelotinib works to block the JAK-signal transducer and activator of transcription (STAT) signalling pathway, which is aberrant in MF.[A261561, A261566, A261571] … [A261566] First approved by the FDA on September 15, 2023,[L48206] momelotinib is used to treat myelofibrosis.
Synonyms: N-(CYANOMETHYL)-4-(2-(4-MORPHOLINOANILINO)PYRIMIDIN-4-YL)BENZAMIDEToripalimab
go.drugbank.com/drugs/DB15043ApprovedInvestigationalIt was first approved in China in December 2018 for the treatment of unresectable or metastatic melanoma in previously treated patients. … [A262011,A262591] Toripalimab was granted FDA approval in October 2023 for the treatment of select patients with nasopharyngeal carcinomas.[L48696]
Alverine
go.drugbank.com/drugs/DB01616ApprovedInvestigationalWithdrawnAlverine is a smooth muscle relaxant used to relieve cramps or spasms of the stomach and intestines. It is therefore useful in treating irritable bowel syndrome (IBS) and similar conditions. … It can also be used to help relieve period pain.
Categories: Drugs for Functional Gastrointestinal DisordersSynonyms: N,N-Bis(3-phenylpropyl)ethylamine, N-Ethyl-N-(3-phenylpropyl)benzenepropanamineMirdametinib
go.drugbank.com/drugs/DB07101ApprovedInvestigationalMirdametinib is a mitogen-activated protein kinase (MAP2K, MEK, MAPKK) inhibitor. On February 11, 2025, mirdametinib was approved by the FDA for the treatment of neurofibromatosis type 1 (NF1). … [L52485] NF1 is an autosomal-dominant genetic condition caused by loss-of-function variants in the _NF1_ tumour suppressor gene,[A265065,A265070] leading to neurofibromin dysfunction and aberrant activation
Synonyms: (-)-N-(((R)-2,3-DIHYDROXYPROPYL)OXY)-3,4-DIFLUORO-2-((2-FLUORO-4-IODOPHENYL)AMINO)BENZAMIDE, N-(((R)-2,3-DIHYDROXYPROPYL)OXY)-3,4-DIFLUORO-2-((2-FLUORO-4-IODOPHENYL)AMINO)BENZAMIDEPirfenidone
go.drugbank.com/drugs/DB04951ApprovedInvestigational[A251370] It is an antifibrotic agent with anti-inflammatory and antioxidant properties [A251370] that is used to treat idiopathic pulmonary fibrosis (IPF),[L26801] which is a chronic, progressive form … [A251370] While its mechanism of action is not yet fully understood, pirfenidone is proposed to primarily regulate tumor necrosis factor (TNF) pathways and modulate cellular oxidation.
Categories: Analgesics, Non-NarcoticLuliconazole
go.drugbank.com/drugs/DB08933ApprovedInvestigationalIt was approved by the FDA (USA) in November 2013 and is marketed under the brand name Luzu. Luliconazole is also approved in Japan. … Luliconazole is a topical antifungal agent that acts by unknown mechanisms but is postulated to involve altering the synthesis of fungi cell membranes.
Categories: Antifungals for Topical Use, Antifungals for Dermatological UseAcetyl sulfisoxazole
go.drugbank.com/drugs/DB14033ApprovedVet approvedSulfisoxazole acetyl competes with PABA for the bacterial enzyme, _dihydropteroate synthase_, preventing the incorporation of PABA into dihydrofolic acid, which is the precursor of folic acid. … It is often combined with erythromycin to treat acute otitis media caused by the bacteria, haemophilus influenzae [L2790].
Cefapirin
go.drugbank.com/drugs/DB01139ApprovedVet approvedProduction for use in humans has been discontinued in the United States. Cefapirin is partly plasma-bound and is effective against gram-negative and gram-positive organisms. … Cefapirin (INN, also spelled cephapirin), commonly marketed under the trade name Cefadyl, is a first-generation cephalosporin antibiotic that is available in injectable formulations.
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseUC-781
go.drugbank.com/drugs/DB05871InvestigationalUC-781 is a thiocarboxanilide non-nucleoside reverse transcriptase inhibitor (NNRTI). It is a topical microbicide targeted against the AIDS virus.
Zapomeran
go.drugbank.com/drugs/DB21761ApprovedZapomeran, marketed under the brand name Kostaive (ARCT-154), is a self-amplifying mRNA COVID-19 vaccine for individuals 18 years and older. … Self-amplification allows for the use of lower doses while providing higher immunogenicity compared to a conventional mRNA COVID-19 vaccine.